LABOMAR, an Italian Group, has acquired Pharmia Oy, a Finnish contract manufacturer, for an undisclosed amount. This corporate acquisition sees LABOMAR taking full ownership of Pharmia, integrating its operations into the Group. Pharmia Oy specializes in the development and manufacturing of top-quality food supplements and CE-marked medical devices. With over 30 years of experience, the company is known for its extensive R&D capabilities and production of over 2,000 unique formulations for a broad base of domestic and international customers.
Based in Tuusula, Finland, Pharmia employs over 90 professionals and offers comprehensive solutions from concept to market-ready products. Its operations are founded on strong scientific expertise, innovation, and a client-focused approach. Notably, Pharmia was the first company in the EU to receive MDR 2017/745 certification for nasal sprays in class IIa in 2022, underscoring its commitment to stringent quality and regulatory standards, including ISO 13485 and FSSC 22000 certifications.
This acquisition is strategically significant for LABOMAR, enabling it to expand its manufacturing footprint and enhance its product and service portfolio within the health and wellness sector. The integration of Pharmia’s expertise in medical device development and contract manufacturing, particularly its advanced regulatory compliance, provides LABOMAR with expanded capabilities and access to new markets. Synergies are expected in leveraging Pharmia’s scientific R&D, production capacities, and established customer relationships to strengthen the combined entity’s international presence and offering.
The combination of LABOMAR and Pharmia Oy aims to create a more robust and diversified entity, better positioned to serve a growing global demand for high-quality food supplements and medical devices. The newly merged operations are anticipated to drive continued innovation and deliver comprehensive solutions to clients worldwide.